Logo image of AMAM

NEW AMBRX BIOPHARMA INC (AMAM) Stock Fundamental Analysis

USA - NASDAQ:AMAM - US6418711080 - Common Stock

28 USD
+0.02 (+0.07%)
Last: 3/6/2024, 8:00:01 PM
28 USD
0 (0%)
After Hours: 3/6/2024, 8:00:01 PM
Fundamental Rating

4

Overall AMAM gets a fundamental rating of 4 out of 10. We evaluated AMAM against 534 industry peers in the Biotechnology industry. AMAM has a great financial health rating, but its profitability evaluates not so good. AMAM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AMAM has reported negative net income.
AMAM Yearly Net Income VS EBIT VS OCF VS FCFAMAM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

AMAM has a better Return On Assets (-30.43%) than 72.73% of its industry peers.
AMAM has a better Return On Equity (-34.09%) than 78.28% of its industry peers.
Industry RankSector Rank
ROA -30.43%
ROE -34.09%
ROIC N/A
ROA(3y)-31.71%
ROA(5y)N/A
ROE(3y)-38.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AMAM Yearly ROA, ROE, ROICAMAM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AMAM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMAM Yearly Profit, Operating, Gross MarginsAMAM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 -200 -400 -600 -800 -1K

More info and screens

9

2. Health

2.1 Basic Checks

AMAM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AMAM has about the same amount of shares outstanding.
There is no outstanding debt for AMAM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AMAM Yearly Shares OutstandingAMAM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 50M 100M 150M 200M 250M
AMAM Yearly Total Debt VS Total AssetsAMAM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

AMAM has an Altman-Z score of 254.13. This indicates that AMAM is financially healthy and has little risk of bankruptcy at the moment.
AMAM has a Altman-Z score of 254.13. This is amongst the best in the industry. AMAM outperforms 99.66% of its industry peers.
AMAM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 254.13
ROIC/WACCN/A
WACC8.93%
AMAM Yearly LT Debt VS Equity VS FCFAMAM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 12.78 indicates that AMAM has no problem at all paying its short term obligations.
The Current ratio of AMAM (12.78) is better than 84.51% of its industry peers.
AMAM has a Quick Ratio of 12.78. This indicates that AMAM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 12.78, AMAM belongs to the top of the industry, outperforming 84.51% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.78
Quick Ratio 12.78
AMAM Yearly Current Assets VS Current LiabilitesAMAM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for AMAM have decreased strongly by -16.00% in the last year.
The Revenue has decreased by -0.80% in the past year.
The Revenue for AMAM have been decreasing by -10.47% on average. This is quite bad
EPS 1Y (TTM)-16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-0.8%
Revenue growth 3Y-10.47%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -25.23% on average over the next years. This is quite bad
AMAM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.47% yearly.
EPS Next Y-159.66%
EPS Next 2Y-135.39%
EPS Next 3Y-38.21%
EPS Next 5Y-25.23%
Revenue Next Year-57.14%
Revenue Next 2Y-45.32%
Revenue Next 3Y-4.12%
Revenue Next 5Y38.47%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AMAM Yearly Revenue VS EstimatesAMAM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
AMAM Yearly EPS VS EstimatesAMAM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AMAM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMAM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMAM Price Earnings VS Forward Price EarningsAMAM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMAM Per share dataAMAM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

A cheap valuation may be justified as AMAM's earnings are expected to decrease with -38.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-135.39%
EPS Next 3Y-38.21%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMAM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEW AMBRX BIOPHARMA INC

NASDAQ:AMAM (3/6/2024, 8:00:01 PM)

After market: 28 0 (0%)

28

+0.02 (+0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-16 2023-11-16/bmo
Earnings (Next)03-26 2024-03-26
Inst Owners0.01%
Inst Owner Change0%
Ins Owners8.9%
Ins Owner Change0%
Market Cap12.42B
Revenue(TTM)5.68M
Net Income(TTM)-82630000
Analysts75.71
Price Target29.07 (3.82%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-210.42%
Min EPS beat(2)-261.73%
Max EPS beat(2)-159.1%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-8.41%
Min Revenue beat(2)-93.6%
Max Revenue beat(2)76.78%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)24.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)51.11%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)72.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)65.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2186.12
P/FCF N/A
P/OCF N/A
P/B 51.23
P/tB 57.06
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-1.64
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.01
BVpS0.55
TBVpS0.49
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.43%
ROE -34.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.71%
ROA(5y)N/A
ROE(3y)-38.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.78
Quick Ratio 12.78
Altman-Z 254.13
F-ScoreN/A
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)73.51%
Cap/Depr(5y)N/A
Cap/Sales(3y)19.68%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-159.66%
EPS Next 2Y-135.39%
EPS Next 3Y-38.21%
EPS Next 5Y-25.23%
Revenue 1Y (TTM)-0.8%
Revenue growth 3Y-10.47%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-57.14%
Revenue Next 2Y-45.32%
Revenue Next 3Y-4.12%
Revenue Next 5Y38.47%
EBIT growth 1Y-3.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.36%
EBIT Next 3Y0.2%
EBIT Next 5YN/A
FCF growth 1Y-45.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-53.85%
OCF growth 3YN/A
OCF growth 5YN/A

NEW AMBRX BIOPHARMA INC / AMAM FAQ

What is the ChartMill fundamental rating of NEW AMBRX BIOPHARMA INC (AMAM) stock?

ChartMill assigns a fundamental rating of 4 / 10 to AMAM.


What is the valuation status of NEW AMBRX BIOPHARMA INC (AMAM) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEW AMBRX BIOPHARMA INC (AMAM). This can be considered as Overvalued.


What is the profitability of AMAM stock?

NEW AMBRX BIOPHARMA INC (AMAM) has a profitability rating of 1 / 10.


What is the expected EPS growth for NEW AMBRX BIOPHARMA INC (AMAM) stock?

The Earnings per Share (EPS) of NEW AMBRX BIOPHARMA INC (AMAM) is expected to decline by -159.66% in the next year.